Sign in with Google
bullish
China Healthcare Weekly (Apr.7)- Pacemaker VBP, FDA Changes Game Rule, Industry Beta Vs Fundamentals
521 Views09 Apr 2023 02:55
China starts pacemaker VBP, which worth investors' vigilance. FDA changes game rules on accelerated approval standards. Beta disappears without fundamentals, which include objective facts + consensus.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Toyota Industries (6201) - Thinking About How To Value a ¥6trln Bid
- UK: Tax Hikes Disrupt Housing Market
- Shibaura Elec (6957) - Minebea Overbids Yageo's Overbid of Minebea's Overbid of Yageo - ¥5,500
- Swiggy (SWIGGY IN): Post-IPO Global Index Inclusion & Final Lockup Expires In May 2025
- Meilan Airport (357 HK): Possible Unconditional MGO at HK$10.62
Discussions
(Paid Plans Only)
- Sinopharm Group Co (1099.HK) - Double-Digit Growth Is Expected in 2023; Margins Have Room to Improve19 Apr 2023
- Pre-IPO New Ruipeng Pet Group (RPET.US) - The Potential Failure of Pet Healthcare and the Bleak IPO17 Apr 2023
- China Healthcare Weekly (Apr.14)- Surgical Robot VBP, Only 5 Biotech to Stand Out, Jafron Biomedical16 Apr 2023
- Sino Biopharmaceutical (1177.HK) - The Positives and the Negatives07 Apr 2023
- ClouDr Group (9955.HK) - “A Dark Horse” to Beat JD Health05 Apr 2023
- Akeso Biopharma (9926.HK) - Behind the Outstanding Performance in 2022 and the Potential Challenges20 Mar 2023
x